Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program

Antimicrob Agents Chemother. 2003 Aug;47(8):2696-8. doi: 10.1128/AAC.47.8.2696-2698.2003.

Abstract

Resistance to quinupristin-dalfopristin (Q/D) among gram-positive cocci has been very uncommon. Two clinical isolates among 8,837 (0.02%) Streptococcus pneumoniae isolates were discovered in 2001 to 2002 with Q/D MICs of 4 micro g/ml. Each had a 5-amino-acid tandem duplication (RTAHI) in the L22 ribosomal protein gene (rplV) preventing synergistic ribosomal binding of the streptogramin combination. Similar gene duplication has been reported in Q/D-resistant Staphylococcus aureus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Base Sequence
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Bacterial
  • Humans
  • Molecular Sequence Data
  • Mutation / genetics*
  • Pneumonia, Pneumococcal / microbiology*
  • Population Surveillance
  • RNA-Binding Proteins / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribosomal Proteins*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics*
  • United Kingdom
  • Virginiamycin / analogs & derivatives*
  • Virginiamycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • RNA-Binding Proteins
  • Ribosomal Proteins
  • Virginiamycin
  • RPL22 protein, human
  • quinupristin